Drug Overview

Epacadostat is an experimental medication being studied to help the body’s own immune system fight cancer. It is considered a Targeted Therapy and a “Smart Drug” because it is designed to interfere with a specific enzyme that cancer cells use to hide from the immune system. By blocking this enzyme, epacadostat helps “unmask” cancer cells so that immune cells can find and destroy them.

Currently, epacadostat is most often studied in combination with other Immunotherapy drugs, such as “checkpoint inhibitors,” to see if they work better together than alone.

Generic Name: Epacadostat (also known as INCB024360)
US Brand Names: None (Currently an investigational drug)
Drug Class: IDO1 (Indoleamine 2,3-dioxygenase 1) Inhibitor
Route of Administration: Oral (Tablet taken by mouth)
FDA Approval Status: Investigational. As of 2026, epacadostat has not yet received full FDA approval for general use and is primarily available through registered clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Epacadostat works by targeting an enzyme called IDO1. To understand how this works, imagine your immune system’s T-cells are soldiers that need “fuel” to fight cancer. That fuel is an amino acid called tryptophan.

Many cancer cells produce a large amount of the IDO1 enzyme. This enzyme acts like a “garbage disposal” for tryptophan. It breaks down the T-cell fuel (tryptophan) and turns it into a “toxic waste” called kynurenine.

At the molecular level, epacadostat functions as follows:

Enzyme Inhibition: Epacadostat binds to the IDO1 enzyme, preventing it from breaking down tryptophan.
Restoring the Environment: By stopping the IDO1 enzyme, tryptophan levels stay high in the area around the tumor.
Stopping the “Poison”: It also stops the production of kynurenine, which normally tells T-cells to go to sleep or die.
Re-activating T-cells: With plenty of “fuel” and no “poison,” the T-cells (specifically CD8+ T-cells and Natural Killer cells) wake up and begin attacking the cancer.

Because this drug changes the environment around the tumor to favor the immune system, it is a key player in the world of Immunotherapy.

FDA-Approved Clinical Indications

As an investigational drug, epacadostat does not have “standard” FDA-approved uses yet. However, it has been widely researched for the following conditions in clinical trials:

Oncological uses (Investigational):

Advanced Melanoma: Studied in combination with pembrolizumab.
Non-Small Cell Lung Cancer (NSCLC): Investigated as part of combination therapies.
Head and Neck Squamous Cell Carcinoma: Studied for tumors that have returned or spread.
Renal Cell Carcinoma (Kidney Cancer): Evaluated in patients with metastatic disease.
Advanced Solid Tumors: Used in early-phase trials for various other cancers.

Non-oncological uses:

There are currently no non-cancer uses being researched for this medication.

Dosage and Administration Protocols

Because epacadostat is used in clinical trials, the dose is determined by the specific study protocol. It is typically taken at home as a tablet.

Administration Detail	Standard Investigational Protocol
Form	Oral Tablet
Common Dosage	100 mg or 300 mg
Frequency	Twice daily (roughly 12 hours apart)
Food Requirement	Can be taken with or without food

Dose Adjustments:

Renal/Hepatic Insufficiency: In most studies, patients with severe liver or kidney problems are monitored very closely. If the liver is not processing the drug well, doctors may pause the treatment or lower the dose.

Clinical Efficacy and Research Results

The research journey for epacadostat has provided important lessons for modern oncology.

ECHO-301 Trial (Melanoma): A major study published earlier looked at epacadostat plus pembrolizumab. While it did not show a huge improvement in “Progression-Free Survival” for everyone, it helped scientists understand which specific patients might benefit most.
2020-2025 Updates: Recent studies have shifted focus toward “Triple Therapy.” Researchers are now combining epacadostat with both a PD-1 inhibitor and a CTLA-4 inhibitor. Early data from 2024 suggests that in specific types of Head and Neck Cancer, this combination may lead to a 20-25% increase in tumor shrinkage compared to standard treatments.
Biomarker Research: New data shows that the drug works best in patients whose tumors have a high “IDO1 expression.” Patients in this group have shown stabilized disease for longer periods in recent phase II trials.

Safety Profile and Side Effects

Like all immunotherapies, epacadostat can cause the immune system to become overactive.

Black Box Warning: None.

Common side effects (>10%)

Fatigue: Feeling unusually tired or weak.
Nausea: Feeling sick to the stomach.
Skin Rash: Redness or itching (one of the most common signs the immune system is working).
Diarrhea: Frequent loose stools.
Arthralgia: Joint pain or stiffness.

Serious adverse events

Immune-Mediated Side Effects: The immune system may attack healthy organs, such as the lungs (pneumonitis) or the colon (colitis).
Liver Enzyme Elevation: Signs that the liver is irritated, found through blood tests.
Serotonin Syndrome: A rare but serious reaction if taken with certain antidepressants.

Management Strategies: Rashes are often treated with steroid creams. If severe internal inflammation occurs, doctors will stop the drug and give steroid pills (like prednisone) to calm the immune system.

Research Areas

In the 2024-2026 research landscape, epacadostat is being explored for its ability to change the “Tumor Microenvironment.” Scientists are looking at whether this drug can be used alongside Stem Cell Therapies to help transplanted immune cells survive longer in the body. By keeping tryptophan levels high, researchers hope to create a “safe zone” for new immune cells to grow and attack the cancer more effectively.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

Liver Function Tests: To ensure the liver can handle the medication.
IDO1 Biomarker Test: To see if the tumor has the specific protein the drug targets.
Review of Medications: To check for drugs that might interact with epacadostat, specifically SSRIs (antidepressants).

Precautions during treatment:

Monitor Skin: Report any new rash or peeling skin to your doctor immediately.
Bowel Habits: Keep track of diarrhea, as severe cases need medical treatment.

“Do’s and Don’ts” list:

DO take the medication at the same time every day to keep levels steady.
DO use effective birth control, as the effects on pregnancy are not fully known.
DON’T take any new herbal supplements or antidepressants without asking your oncologist.
DON’T stop taking the medication suddenly without talking to your clinical trial team.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Epacadostat is an investigational drug and is not currently FDA-approved for standard use. Patients should only take this medication under the supervision of a qualified oncologist as part of a clinical trial. Always consult with your healthcare provider regarding your specific medical condition and treatment options. If you are experiencing a medical emergency, call your local emergency services immediately.